Sabra Health Care REIT (NASDAQ: SBRA) reported second-quarter 2026 revenue of $235.866 million, beating analyst estimates of $219.689 million by 7.36 percent and rising 24.70 percent year-over-year from $189.150 million. Despite a GAAP net loss of $(0.10) per diluted share due to significant loan loss provisions, the healthcare real estate investment trust delivered resilient operational performance with Normalized Adjusted Funds From Operations (AFFO) of $0.40 per share. The company also declared a quarterly cash dividend of $0.30 per share, payable on August 31, 2026, to stockholders of record as of August 14, 2026.

The financial results were heavily influenced by non-operational charges. Sabra recorded a provision for loan losses and other reserves of $102.4 million for the quarter, compared to a recovery of $0.2 million in the same period last year. This charge drove the net loss attributable to Sabra Health Care REIT, Inc. to $25.2 million, reversing the net income of $65.5 million reported in the second quarter of 2025. Excluding these items, Funds From Operations (FFO) stood at $(0.02) per share, while Normalized FFO reached $0.38 per share. The reported FFO of $0.39 per share met analyst consensus estimates, representing a 5.41 percent increase over the $0.37 per share reported in the same period last year.

Operational Highlights and Investment Activity

Sabra’s core operations showed strength across its portfolio segments. Same-property managed senior housing Cash NOI grew 13.7% year-over-year. EBITDARM coverage ratios remained robust, particularly in the Behavioral Health, Specialty Hospitals and Other segment at 4.14x, followed by Skilled Nursing/Transitional Care at 2.49x and Senior Housing - Leased at 1.52x.

In terms of capital deployment, Sabra closed on several senior housing and skilled nursing investments during the quarter totaling $274.1 million, yielding an average initial cash yield of 8.1%. Year-to-date investments reached $599.0 million with an estimated initial cash yield of 7.5%. Additionally, the company secured an additional $100 million in managed senior housing and skilled nursing investments, expected to close by year-end with an estimated initial cash yield of approximately 7.7%.

Liquidity and Balance Sheet

As of June 30, 2026, Sabra maintained total liquidity of approximately $1.3 billion. This consisted of unrestricted cash and cash equivalents of $231.6 million, available borrowings under its revolving credit facility of $682.5 million, and $411.8 million related to shares outstanding under forward sale agreements via its at-the-market equity offering program. The company’s Net Debt to Adjusted EBITDA ratio decreased to 4.61x from 4.8x noted in its previous business update.

During the quarter, Sabra exercised its option to reset rent under its lease with the Avamere Family of Companies to a fixed amount tied to historical performance. This reset increased annualized fixed cash rent to $48 million, retroactive to February 1, 2026, up from $41 million paid in 2025. The revised rent structure remains in effect until the Avamere transition closes.

What the Numbers Show

The divergence between GAAP net income and non-GAAP metrics highlights the impact of credit provisioning on Sabra’s reported earnings. While the GAAP net loss of $(0.10) per share suggests deterioration, the Normalized AFFO increase to $0.40 per share indicates stable underlying cash generation capabilities. The substantial loan loss provision of $102.4 million was the primary driver of the GAAP loss, rather than a decline in rental revenues or operating margins. This pattern suggests that while asset quality concerns exist within the loan portfolio, the core real estate operations continue to generate positive cash flow and support the declared dividend. The beat on revenue estimates further underscores the strength of the underlying portfolio despite the headwinds from credit reserves.

Rick Matros, CEO and Chair, stated that the company delivered another solid quarter with healthy same-store managed portfolio cash NOI growth and increased occupancy across both consolidated and unconsolidated portfolios. Sabra reiterated its full-year 2026 guidance as previously disclosed in its July 21, 2026, business update.

Sabra Health Care REIT (NASDAQ: SBRA) lowered its funds from operations (FFO) guidance for fiscal year 2026, signaling a more conservative outlook for the healthcare real estate investment trust. The company revised its full-year FFO range downward from $1.55 to $1.59 to a new range of $1.53 to $1.55 per share. This adjustment places the upper end of the company’s guidance exactly at the consensus analyst estimate of $1.55, while the lower bound dips below market expectations. The reduction in guidance highlights potential headwinds or operational adjustments affecting the firm’s projected cash flow from operations for the year.

The revision reflects a tightening of the expected performance band, with the midpoint of the new guidance sitting at $1.54, compared to the previous midpoint of $1.57. By lowering the floor of its estimate to $1.53, Sabra Health Care REIT is effectively acknowledging risks that may constrain its ability to generate higher operational returns. The move contrasts with the prior guidance, which offered a wider buffer above the analyst consensus. Investors will need to assess whether this shift indicates temporary volatility or a structural change in the company’s growth trajectory for FY26.

Guidance Revision Details

The following table outlines the change in Sabra Health Care REIT’s FFO guidance for fiscal year 2026:

The alignment of the revised upper bound with the analyst estimate suggests that management is adopting a cautious stance, potentially reserving upside for later in the year if conditions improve. Conversely, the lower bound of $1.53 introduces a downside risk that was not present in the earlier forecast. This narrowing of the range reduces the margin of safety for investors relying on the previous higher estimates.

What the Numbers Show

The decision to cut guidance by approximately $0.04 at the midpoint level is material for a REIT, where FFO serves as a key proxy for earnings power and dividend sustainability. The fact that the new ceiling matches the street’s expectation implies that Sabra Health Care REIT is no longer anticipating outperformance relative to consensus views. Instead, the company appears to be prioritizing accuracy over optimism, ensuring that its public commitments are achievable under current market conditions. This shift may influence investor sentiment, particularly among those who value predictable cash flows in the healthcare real estate sector.